Revvity and Lilly Collaborate on AI Drug Discovery Models Expansion

Revvity has collaborated with Lilly to expand access to Lilly's AI drug discovery models through Revvity's Signals Xynthetica platform. The collaboration will make Lilly's predictive models available to participating biotechs, who can use them to accelerate their drug discovery programs. Revvity's Models-as-a-Service framework and Signals Xynthetica offering enable secure and private access to the models, amplifying the value of contributions from small and mid-sized biotechs. Lilly and Revvity will jointly fund access for selected participants.